These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

108 related items for PubMed ID: 1394824

  • 1. Factors affecting the outcome of patients with advanced urothelial cancer following chemotherapy with methotrexate, vinblastine, adriamycin, and cisplatin.
    Igawa M, Ohkuchi T, Ueda M, Usui T.
    Cancer Chemother Pharmacol; 1992; 30 Suppl():S77-80. PubMed ID: 1394824
    [Abstract] [Full Text] [Related]

  • 2. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
    Igawa M, Kadena H, Ohkuchi T, Ueda M, Usui T.
    Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701
    [Abstract] [Full Text] [Related]

  • 3. Clinical and pathological evaluations of methotrexate, vinblastine, adriamycin and cisplatin chemotherapy for advanced urothelial cancers.
    Ogawa T, Gotoh A, Takenaka A, Hara I, Gohji K, Arakawa S, Matsumoto O, Kamidono S.
    Cancer Chemother Pharmacol; 1992 Oct; 30 Suppl():S66-71. PubMed ID: 1394822
    [Abstract] [Full Text] [Related]

  • 4. Methotrexate, vinblastine, adriamycin and cisplatin versus methotrexate and cisplatin in advanced urothelial cancer. A randomized study.
    Pizzocaro G, Milani A, Piva L, Faustini M, Spino E.
    Eur Urol; 1991 Oct; 20(2):89-92. PubMed ID: 1752280
    [Abstract] [Full Text] [Related]

  • 5. [Experience with combination chemotherapy consisting of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer].
    Nishio Y, Shirahase T, Shichiri Y, Habuchi T, Matsuda T, Nishimura K, Hida S, Okada Y, Yoshida O.
    Hinyokika Kiyo; 1988 Aug; 34(8):1371-5. PubMed ID: 3195405
    [Abstract] [Full Text] [Related]

  • 6. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Heineman M, Hirsch J, Kelly WK, Scher HI, Bajorin DF.
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [Abstract] [Full Text] [Related]

  • 7. Factors related to the outcome of M-VAC in 101 patients with advanced urothelial cancer.
    Igawa M, Urakami S, Shirakawa H, Shiina H, Ishibe T, Kadena H, Usui T, Kawanishi M.
    Hiroshima J Med Sci; 1995 Dec; 44(4):113-7. PubMed ID: 8857234
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Japanese Urothelial Cancer Research Group.
    Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T.
    Jpn J Clin Oncol; 1998 Aug; 28(8):497-501. PubMed ID: 9769784
    [Abstract] [Full Text] [Related]

  • 11. [Clinical evaluation of M-VAC chemotherapy (methotrexate, vinblastine, adriamycin and cisplatin) for advanced urothelial cancer].
    Gohji K, Takenaka A, Goto A, Hara I, Matsumoto O, Kamidono S, Hamami G, Itani A, Harada K, Tadera N.
    Nihon Hinyokika Gakkai Zasshi; 1989 Mar; 80(3):321-8. PubMed ID: 2659869
    [Abstract] [Full Text] [Related]

  • 12. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, Geller N, Hollander PS, Herr HW, Sogani PC.
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [Abstract] [Full Text] [Related]

  • 13. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced urothelial cancer.
    Ueki O, Hisazumi H, Uchibayashi T, Naito K, Tajiri S, Takemae K, Kawaguchi K, Kameda K, Nishino A, Nango C.
    Cancer Chemother Pharmacol; 1992 Mar; 30 Suppl():S72-6. PubMed ID: 1394823
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N, Akaza H, Shimazui T, Ohtani M, Koiso K.
    Cancer Chemother Pharmacol; 1994 Mar; 35 Suppl():S5-8. PubMed ID: 7527735
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cisplatin-based chemotherapy for the treatment of advanced transitional-cell carcinoma of the urinary tract--a preliminary report.
    Lee MH, Chen MT, Chen KK, Lin AT, Lee YH, Lee LM, Chang YM, Chang LS, Liu JM, Hsieh RK.
    Cancer Chemother Pharmacol; 1992 Mar; 30 Suppl():S81-4. PubMed ID: 1394825
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.